Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals and Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer’s disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington’s disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Latest Biotechnology and ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals, Inc. Stock News

As of May 7, 2026, ACADIA Pharmaceuticals Inc. had a $3.9 billion market capitalization, compared to the Biotechnology median of $275.8 million. ACADIA Pharmaceuticals Inc.’s stock is down 15.3% in 2026, up 3% in the previous five trading days and up 55.19% in the past year.

Currently, ACADIA Pharmaceuticals Inc.’s price-earnings ratio is 9.8. ACADIA Pharmaceuticals Inc.’s trailing 12-month revenue is $1.1 billion with a 34.3% net profit margin. Year-over-year quarterly sales growth most recently was 9.4%. Analysts expect adjusted earnings to reach $0.395 per share for the current fiscal year. ACADIA Pharmaceuticals Inc. does not currently pay a dividend.

As of May 7, 2026, Syndax Pharmaceuticals, Inc. had a $1.8 billion market cap, putting it in the 53rd percentile of all stocks. Syndax Pharmaceuticals, Inc.’s stock is down 0.9% in 2026, up 8.8% in the previous five trading days and up 93.05% in the past year.

Currently, Syndax Pharmaceuticals, Inc. does not have a price-earnings ratio. Syndax Pharmaceuticals, Inc.’s trailing 12-month revenue is $217.2 million with a -112.0% net profit margin. Year-over-year quarterly sales growth most recently was 224.5%. Analysts expect adjusted earnings to reach $-1.746 per share for the current fiscal year. Syndax Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals and Inc. Growth Grades

Company	Ticker	Growth
ACADIA Pharmaceuticals Inc.	ACAD	D
Syndax Pharmaceuticals, Inc.	SNDX	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

ACADIA Pharmaceuticals Inc. has a Growth Score of 37, which is Weak. Syndax Pharmaceuticals, Inc. has a Growth Score of 7, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals or Inc. is the better investment when it comes to sustainable growth.

ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
ACADIA Pharmaceuticals Inc.	ACAD	B
Syndax Pharmaceuticals, Inc.	SNDX	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

ACADIA Pharmaceuticals Inc. has a Quality Score of 79, which is Strong. Syndax Pharmaceuticals, Inc. has a Quality Score of 6, which is Very Weak.

The Quality Grade Winner: ACADIA Pharmaceuticals Inc.

As you can clearly see from the Quality Grade breakdown above, ACADIA Pharmaceuticals Inc. has a better overall quality grade than Syndax Pharmaceuticals, Inc.. For investors who are looking for companies with higher quality than others in the same industry, ACADIA Pharmaceuticals Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
ACADIA Pharmaceuticals Inc.	ACAD	D
Syndax Pharmaceuticals, Inc.	SNDX	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

ACADIA Pharmaceuticals Inc. has a Earnings Estimate Score of 33, which is Negative. Syndax Pharmaceuticals, Inc. has a Earnings Estimate Score of 39, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals or Inc. is the better investment when it comes to estimate revisions.

Other ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals and Inc. Grades

In addition to Growth, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals or Inc. Stock?

Overall, ACADIA Pharmaceuticals Inc. stock has a Growth Score of 37, Estimate Revisions Score of 33 and Quality Score of 79.

Syndax Pharmaceuticals, Inc. stock has a Growth Score of 7, Estimate Revisions Score of 39 and Quality Score of 6.

Comparing ACADIA Pharmaceuticals Inc., Syndax Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.